9 news items
MAIA Biotechnology (NYSE: MAIA) Makes Strategic Moves: Key Presentations, New Funding, and Leadership Changes Drive Innovation
ABBV
JNJ
LLY
21 May 24
an investment advisor nor a registered broker. No current owner, employee, or independent contractor of InvestorBrandMedia.com is registered
Actinium Pharmaceuticals (NYSE: ATNM): A Prime Target in a Wave of Radiopharmaceutical Mergers and Acquisitions
ABBV
ATNM
AZN
8 May 24
is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of InvestorBrandMedia.com is registered
Pfizer Embraces Direct-To-Consumer Model For Covid Antiviral, Says Comirnaty Revenues Continue To Perform Consistently With Expectations
LLY
PFE
1 May 24
.
The platform, which is slated for launch later this year, will facilitate connections between U.S. customers and independent telehealth
Investment Opportunities in Biotech Amidst Federal Rate Uncertainties (ATNM)
ABBV
ATNM
AZN
22 Apr 24
advisor nor a registered broker. No current owner, employee, or independent contractor of InvestorBrandMedia.com is registered as a securities broker
Actinium Pharmaceuticals (ATNM) Leads Biotech Innovation Amid Economic Uncertainty
ABBV
ATNM
AZN
19 Apr 24
is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of InvestorBrandMedia.com
8aey2hjpjtovem65uc55kvdmr1cr1lsqpab71mo2eugo
ATNM
AZN
BMY
18 Apr 24
. No current owner, employee, or independent contractor of InvestorBrandMedia.com is registered as a securities broker-dealer, broker, investment advisor
qae8g6 2p2zuv308ic7pf8yrvps9rhojm1gbv30f5h
BEAM
LLY
VERV
2 Apr 24
independent data and safety monitoring board (DSMB), Verve has decided to pause enrollment in the Heart-1 clinical trial.
Verve
zx2z7dc8ubfd179ukil4ql7helok6zr2wilz9
AMZN
LLY
13 Mar 24
.
LillyDirect offers disease management resources, including access to independent healthcare providers, tailored support, and direct home delivery
1fh0cpetg9dcuipv93b2jaxj
LLY
NVO
12 Mar 24
, the Independent Data Monitoring Committee advised Novo Nordisk to prematurely conclude its kidney outcomes trial, FLOW, following an interim analysis
- Prev
- 1
- Next